Steven M Paul bought $1.0M of Rapport Therapeutics (RAPP)
Executed Sep 12 2025, disclosed Sep 15 2025, 3 days later.
Over the 21 trading sessions from the disclosed entry session (Sep 15 2025), the stock returned +10.2% (delay-adjusted); from the execution session (Sep 12 2025), +9.3%. Derived: entry at the session's open, exit at the close 20 sessions later.
Steven M Paul (Director) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in Rapport Therapeutics, Inc. (RAPP). The largest single filing was $974K of RAPP (35,714 sh × $27.28, as filed), executed Oct 22. The median gap between execution and disclosure was 0 days.
Healthcare · Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transfo…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→35,714 sh × $27.28
Exec Oct 22
Filed Oct 22 · 4:56 PM ET